LLY Valuation

Eli Lilly and Co

Add to Watchlist

Advanced Chart

812.690

+7.26(0.901%)1D

Overview
Forecast
Valuation
Earnings

LLY Relative Valuation

LLY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LLY is overvalued; if below, it's undervalued.

Historical Valuation

Eli Lilly and Co (LLY) is now in the Fair zone, suggesting that its current forward PE ratio of 31.89 is considered Fairly compared with the five-year average of 39.49. The fair price of Eli Lilly and Co (LLY) is between 760.92 to 1274.69 according to relative valuation methord.

Relative Value

Fair Zone

760.92-1274.69

Current Price：805.43

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

48.85

P/B

Median3y

45.60

Median5y

39.24

0.52

FCF Yield

Median3y

0.76

Median5y

1.65

Competitors Valuation Multiple

The average P/S ratio for LLY's competitors is 5.68, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY) exhibits a P/S ratio of 11.43, which is 101.42% above the industry average. Given its robust revenue growth of 45.17%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap